Menu
Search
|

Menu

Close
X

Abeona Therapeutics Inc ABEO.OQ (NASDAQ Stock Exchange Capital Market)

7.96 USD
+0.30 (+3.92%)
As of 2:29 AM IST
chart
Previous Close 7.66
Open 7.79
Volume 221,194
3m Avg Volume 187,430
Today’s High 8.03
Today’s Low 7.74
52 Week High 22.00
52 Week Low 6.94
Shares Outstanding (mil) 40.29
Market Capitalization (mil) 713.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
1
FY16
1
FY15
1
EPS (USD)
FY18
-0.771
FY17
-0.653
FY16
-0.637
FY15
-0.523
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.60
Price to Sales (TTM)
vs sector
845.89
5.69
Price to Book (MRQ)
vs sector
8.00
5.11
Price to Cash Flow (TTM)
vs sector
--
23.53
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-29.33
15.05
Return on Equity (TTM)
vs sector
-30.75
16.62

EXECUTIVE LEADERSHIP

Steven Rouhandeh
Executive Chairman of the Board, Since 2015
Salary: $386,000.00
Bonus: $154,000.00
Timothy Miller
President, Chief Scientific Officer, Since 2018
Salary: $375,000.00
Bonus: $150,000.00
Frank Thiel
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Joao Siffert
Executive Vice President, Chief Medical Officer, Head of Research and Development, Since 2018
Salary: --
Bonus: --
Stephen Thompson
Senior Vice President - Finance and Administration, Chief Accounting Officer, Treasurer, Secretary, Since 2015
Salary: $154,080.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3333 Lee Pkwy Ste 600
DALLAS   TX   75219-5117

Phone: +1214.9055100

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

SPONSORED STORIES